Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans

International Journal of Cancer

Volumn 135, Issue 3, 2014, Pages 720-730

  Bramante, Simona ^a   Koski, Anniina ^a   Kipar, Anja ^b,c   Diaconu, Iulia ^a   Liikanen, Ilkka ^a   Hemminki, Otto ^a   Vassilev, Lotta ^a,d   Parviainen, Suvi ^a   Cerullo, Vincenzo ^a   Pesonen, Saila K ^a   Oksanen, Minna ^a   Heiskanen, Raita ^a,d   Rouvinen Lagerström, Noora ^a   Merisalo Soikkeli, Maiju ^a   Hakonen, Tiina ^a,d   Joensuu, Timo ^e   Kanerva, Anna ^a   Pesonen, Sari ^a   Hemminki, Akseli ^a,f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

^d Oncos Therapeutics Inc   (Finland)

^e Docrates Oncology Clinic   (Finland)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Animal models of cancer; Cancer gene therapy; GM CSF; Oncolytic adenovirus; Sarcoma

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NEUTRALIZING ANTIBODY; ONCOLYTIC ADENOVIRUS;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ANEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANOREXIA; ANTIBODY TITER; ARTICLE; BRONCHITIS; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PAIN; CHILL; CHIMERA; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEPRESSION; DIZZINESS; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEMALE; FEVER; FIBROSARCOMA; FLU LIKE SYNDROME; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HIP PAIN; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; HYPERVENTILATION; HYPONATREMIA; HYPOTENSION; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE PAIN; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; LOSS OF APPETITE; LOW DRUG DOSE; MALE; METABOLIC DISORDER; MOUSE; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; PAIN; PLEURAL PAIN; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; RHABDOMYOSARCOMA; RIGOR; SARCOMA; SARCOMA CELL LINE; SEROTYPE; SINUSITIS; SOFT TISSUE SARCOMA; SORE THROAT; SURVIVAL TIME; SYRIAN HAMSTER; T LYMPHOCYTE; THROMBOCYTOPENIA; TUMOR XENOGRAFT; UNSPECIFIED SIDE EFFECT; VERTIGO; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VOMITING; XEROSTOMIA;

ANIMAL MODELS OF CANCER; CANCER GENE THERAPY; GM-CSF; ONCOLYTIC ADENOVIRUS; SARCOMA;

ADENOVIRIDAE; ANIMALS; FEMALE; GENETIC THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; INJECTIONS, INTRALESIONAL; MESOCRICETUS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; PROGNOSIS; SARCOMA; SURVIVAL RATE; TUMOR CELLS, CULTURED; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901035359     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28696     Document Type: Article

References (50)

1. Zahm SH, Fraumeni JF, Jr,. The epidemiology of soft tissue sarcoma. Semin Oncol 1997; 24: 504-14.
2. McClay EF,. Epidemiology of bone and soft tissue sarcomas. Semin Oncol 1989; 16: 264-72.
3. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-58.
4. Kanerva A, Hemminki A,. Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475-80.
5. Wang H, Li ZY, Liu Y, et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 2011; 17: 96-104.
6. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-80.
7. Tuve S, Wang H, Ware C, et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 2006; 80: 12109-20.
8. Bauerschmitz GJ, Barker SD, Hemminki A,. Adenoviral gene therapy for cancer: from vectors to targeted and replication competent agents (review). Int J Oncol 2002; 21: 1161-74.
9. Tuve S, Liu Y, Tragoolpua K, et al. In situ adenovirus vaccination engages T effector cells against cancer. Vaccine 2009; 27: 4225-39.
10. Alemany R,. A smart move against cancer for vaccinia virus. Lancet Oncol 2008; 9: 507-8.
11. Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res 2010; 70: 4297-309.
12. Dranoff G,. GM-CSF-secreting melanoma vaccines. Oncogene 2003; 22: 3188-92.
13. Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004; 64: 6337-43.
14. Arellano M, Lonial S,. Clinical uses of GM-CSF, a critical appraisal and update. Biologics 2008; 2: 13-27.
15. Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 2010; 18: 1874-84.
16. Smyth MJ, Godfrey DI, Trapani JA,. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001; 2: 293-9.
17. Burke JM,. GM-CSF-armed, replication-competent viruses for cancer. Cytokine Growth Factor Rev 2010; 21: 149-51.
18. Pesonen S, Diaconu I, Cerullo V, et al. Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 2012; 130: 1937-47.
19. Amgen announces top-line results of phase 3 talimogene laherparepvec trial in melanoma. Available at: http://www.amgen.com/media/media-pr-detail.jsp? year=2013&releaseID=1798143 Amgen, 2013.
20. Kanerva A, Nokisalmi P, Diaconu I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 2013; 19: 2734-44.
21. Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 2000; 19: 2-12.
22. Sherr CJ,. Cancer cell cycles. Science (New York, NY) 1996; 274: 1672-7.
23. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol 1998; 72: 9706-13.
24. Fleischli C, Sirena D, Lesage G, et al. Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J Gen Virol 2007; 88: 2925-34.
25. Diaconu I, Cerullo V, Escutenaire S, et al. Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir. J Gene Med 2010; 12: 435-45.
26. Raki M, Hakkarainen T, Bauerschmitz GJ, et al. Utility of TK/GCV in the context of highly effective oncolysis mediated by a serotype 3 receptor targeted oncolytic adenovirus. Gene Ther 2007; 14: 1380-8.
27. Hughes DJ, Kipar A, Leeming G, et al. Experimental infection of laboratory-bred bank voles (Myodes glareolus) with murid herpesvirus 4. Arch Virol 2012; 157: 2207-12.
28. Koski A, Raki M, Nokisalmi P, et al. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther 2012; 20: 221-9.
29. Liikanen I, Ahtiainen L, Hirvinen ML, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 2013; 21: 1212-23.
30. Cerullo V, Diaconu I, Kangasniemi L, et al. Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 2011; 19: 1737-46.
31. Koski A, Koskela A, Ahtinen H, et al. [F18]-FDG-PET versus CT for evaluation of oncolytic virus treatment in advanced cancer patients. Mol Ther 2012; 20 (S1): S84 (ASGCT Abstract 213). Available at: http://www.ncbi.nlm.nih. gov/pubmed/24099555.
32. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-70.
33. Shanafelt AB, Johnson KE, Kastelein RA,. Identification of critical amino acid residues in human and mouse granulocyte-macrophage colony-stimulating factor and their involvement in species specificity. J Biol Chem 1991; 266: 13804-10.
34. Cohen AM, Hines DK, Korach ES, et al. In vivo activation of neutrophil function in hamsters by recombinant human granulocyte colony-stimulating factor. Infect Immun 1988; 56: 2861-5.
35. Kanerva A, Nokisalmi P, Tähtinen S, et al. Serial treatment with oncolytic adenovirus results in redistribution of T-cell subsets in humans and mice. Mol Ther 2012; 20 (S1) (ASGCT Abstract 834).
36. Brahmer JR, Drake CG, Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, #clinical |activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28: 3167-75.
37. Alemany R, Suzuki K, Curiel DT,. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000; 81: 2605-9.
38. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol 2001; 19: 289-98.
39. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002; 62: 6070-9.
40. Galanis E, Okuno SH, Nascimento AG, et al. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005; 12: 437-45.
41. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England 1990) 2009; 45: 228-47.
42. Trinh HV, Lesage G, Chennamparampil V, et al. Avidity binding of human adenovirus serotypes 3 and 7 to the membrane cofactor CD46 triggers infection. J Virol 2012; 86: 1623-37.
43. Thomas MA, Spencer JF, La Regina MC, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-6.
44. Jogler C, Hoffmann D, Theegarten D, et al. Replication properties of human adenovirus in vivo and in cultures of primary cells from different animal species. J Virol 2006; 80: 3549-58.
45. Reali E, Canter D, Zeytin H, et al. Comparative studies of Avipox-GM-CSF versus recombinant GM-CSF protein as immune adjuvants with different vaccine platforms. Vaccine 2005; 23: 2909-21.
46. Yigit N, Kryštufek B,. Mesocricetus auratus. Available at: http://www.iucnredlist.org IUCN 2012. IUCN Red List of Threatened Species. Version 2012.2., 2008.
47. McGuire KL, Duncan WR, Tucker PW,. Syrian hamster DNA shows limited polymorphism at class I-like loci. Immunogenetics 1985; 22: 257-68.
48. Khajah M, Millen B, Cara DC, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF): a chemoattractive agent for murine leukocytes in vivo. J Leuk Biol 2011; 89: 945-53.
49. Hemminki A,. Treatment of chemotherapy-refractory cancer in the advanced therapy access program. Mol Ther 2012; 20: 1654-5.
50. Hemminki A, Oksanen M, Merisalo-Soikkeli M,. Oncolytic virotherapy trials-letter. Clin Cancer Res 2013; 19: 4541-2.